NCT06336343

Bimekizumab in Plaque Psoriasis

Name: Clinical Trial NCT06336343
Creator: Icahn School of Medicine at Mount Sinai
Keywords: Plaque Psoriasis, Bimekizumab, Phase 4, drug, clinical trial, United States of America

A Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies

Icahn School of Medicine at Mount Sinai·Phase 4·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Plaque Psoriasis
Drug/Device/Intervention: Bimekizumab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Icahn School of Medicine at Mount Sinai
Location: East Windsor,New York, United States of America

Timeline & enrollment

Phase: Phase 4
Start date: Mar 01, 2024
End date: Oct 31, 2025
Enrollment: 60 participants

Primary outcome

Body Surface Area (BSA) of 1

Summary

The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23.

ICD-10 classifications

PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06336343
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06336343 through Pure Global AI's free database. This Phase 4 trial is sponsored by Icahn School of Medicine at Mount Sinai and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.